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Background: Human Papillomavirus (HPV) is a very resistant, ubiquitous virus that can survive in the environment
without a host. The decision to analyse HPV-related diseases in males was due to the broad dissemination of the
virus, and, above all, by the need to stress the importance of primary and secondary prevention measures (currently
available for women exclusively). The objective of the Consensus Conference was to make evidence-based
recommendations that were designed to facilitate the adoption of a standard approach in clinical practice in Italy.
Methods: The Sponsoring Panel put a series of questions to the members of the Scientific Committee who
prepared a summary of the currently available information, relevant for each question, after the review and grading
of the existing scientific literature. The summaries were presented to a Jury, also called multidisciplinary Consensus
Panel, who drafted a series of recommendations.
Results: The prevalence of HPV in males ranges between 1.3–72.9%. The prevalence curve in males is much higher
than that in females and does not tend to decline with age. Women appear to have a higher probability of
acquiring HPV genotypes associated with a high oncogenic risk, whereas in males the probability of acquiring
low- or high-risk genotypes is similar. The HPV-related diseases that affect males are anogenital warts and cancers
of the penis, anus and oropharynx. The quadrivalent vaccine against HPV has proved to be effective in preventing
external genital lesions in males aged 16–26 years in 90.4% (95% CI: 69.2–98.1) of cases. It has also proved to be
effective in preventing precancerous anal lesions in 77.5% (95% CI: 39.6–93.3) of cases in a per-protocol analysis and
in 91.7% (95% CI: 44.6–99.8) of cases in a post-hoc analysis. Early ecological studies demonstrate reduction of
genital warts in vaccinated females and some herd immunity in males when vaccine coverage is high, although
males who have sex with males gained no benefit at all. Males with an immunodeficiency disease are at greater
risk of developing disease. Infertility seems to be caused by HPV in some cases. Studies demonstrate vaccination to
both genders can be more efficacious and social equity matters are to be taken into consideration.
Conclusions: The Jury made Recommendations based on the scientific evidence presented by the Scientific
Committee. Accordingly, for prevention purposes and social fairness and equality, as both sexes are affected by the
disease, the vaccination of 12-year-old males against HPV should be recommended in order to guaranty protection
to everyone. Aspects related to healthcare policy and economic sustainability, are to be discussed by respective
public system representatives. More campaigns to raise awareness through all institutional channels are needed,
not only regarding anogenital warts, but for HPV-related diseases in general in males in accordance to new
scientific evidences.
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The Human Papillomavirus (HPV) is a very resistant,
ubiquitous virus that can survive in the environment
without a host [1]. It may remain inactive for a long time
and produce asymptomatic infections of the skin. It can
be transmitted from one individual to another directly
(by sexual contact) or indirectly.
The dynamics of heterosexual transmission of HPV
(the major route of infection) are still being investigated
and their relative importance has not been established
yet. The ability of HPV to survive for a long time on va-
rious surfaces, objects, and parts of the body that have
had contact with infected mucous membranes makes
potential transmission to the genitals via the hands, the
perigenital skin (the scrotum or pubis) or even inani-
mate objects possible [2].
HPV has been found on the skin and the mucous mem-
branes of individual exposed to the virus, and causes both
anogenital and oropharyngeal infections. In women, the
prevalence of the different genotypes of HPV has been
determined and analyzed within the setting of cytologic
examinations with the purpose of screening for and diag-
nosing precancerous and cancerous lesions. In men, the
first studies focused on HPV infection and the risk of can-
cer in the homosexual population. More recently, studies
on the importance and clinical consequences of HPV in-
fection have been extended to the heterosexual male po-
pulation, and have also examined the role of males in the
transmission of HPV to women.
The frequency of HPV infection in various groups of
male subjects was analyzed in a systematic review of the
literature, which included 40 papers published from 1999
to 2006 [3]. Overall, the prevalence of HPV in men ranged
from 1.3% to 72.9%, and it exceeded 20% in 56% of the
studies analyzed. In another review, carried out by Partridge
et al. on studies conducted from 1991 to 2005, the preva-
lence of HPV in heterosexual males ranged from 3.5% to
45% [4].
One finding is difficult to explain: the prevalence of HPV
infection in men does not vary among different age groups,
although its incidence is similar in both genders and its
clearance is fairly rapid. A possible explanation is that
repeated infections occur during sexual activity and persist
for variable periods of time. However, a longitudinal assess-
ment of a cohort of males who are followed up in the long
term is needed to provide more information on this phe-
nomenon. The following points have become apparent
with respect to HPV-related diseases in males:
– - Several issues of the diseases are controversial and
should be addressed by adopting a multidisciplinary
and multiprofessional approach;
– - Such diseases are a public health matter and have
aroused the interest of healthcare professionals andusers (patients/citizens), with potential impacts on
clinical practice;
– - The scientific data on these diseases are
incomplete, but nevertheless enable the drafting of a
reliable consensus document that is based on expert
opinions;
– - Exhaustive information on HPV-related diseases in
males is not available, so it is important to make
recommendations for further research;
– - A document that lays down recommendations for
the prevention and management of HPV-related
diseases in males, may reduce variability in
healthcare and, possibly, related costs.
The decision to analyze HPV-related diseases in males
by establishing a Consensus Conference (CC) was due to
the broad dissemination of the virus, and, above all, by the
need to stress the importance of measures for primary
prevention and organized screening programs, which, at
present, are the only tools we have to reduce the incidence
of HPV-related diseases. It is worth noting that in clinical
practice there are neither validated tests nor screening
programs for HPV in males at the moment.
The objective of the CC was to make evidence-based
recommendations, starting from a review of existing litera-
ture that was designed to assess the best scientific evidence
available currently.
Methods
A CC is one of the tools that enable agreement to be
reached, through a formal process, on healthcare issues
that are particularly complex and controversial. The out-
come facilitates a uniform approach to such issues in
clinical practice.
Consensus Conference protocol
The consensus conference on Human Papillomavirus
Diseases in Males was called by a Sponsor Panel (SP),
which included representatives of three Italian scientific
societies: SIA – (Italian Society of Andrology), SIAMS
(Italian Society of Andrology and Sexual Medicine),
SIU (Italian Society of Urology). They appointed ten ack-
nowledged experts in the field to set up the Scientific
Committee (SC) of experts.
In January 2010 the SP gathered the Scientific Committee
to submit four specific predefined questions of importance
to better understand HPV in males about which the SC
was asked to draw a synthesis of the available knowledge
starting from a revision of the scientific literature on the
topics.
The expert panel revised the scientific literature, clas-
sifying it into the following areas:
– - HPV epidemiology
Figure 1 Flow of information to describe the results of the
entire process.
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– - HPV burden of disease
– - HPV prevention strategies
– - HPV vaccines
– - Social impact of HPV diseases
Inclusion criteria and paper selection process were
established in accordance with the Sponsor Panel and
the Panel of experts. To be included in the review, each
paper had to: a) contain data from males or separately
presented from females; and b) contain country-specific/
racial/sexual-habits data for male subjects or c) report
on HPV prevalent in males or d) report on incidence of
HPV–related events in males or f ) report on relationship
between HPV and fertility or g) report results on diag-
nostic testing methods on males or separately presented
from females.
Studies that did not meet criteria a) and b) and at least
one of criteria c), d), f), g) were ineligible. Literature collec-
tion started in January 2010; four coordinators (one for
each question of the Consensus Conference) were en-
charged of retrieving all the relevant documents through
November (2010), following the up-reported selection cri-
teria. Longitudinal, retrospective and cross-sectional stud-
ies, as well as randomized clinical trials were considered,
upon availability. The search process used the following
database to identify articles published until 2010 included:
Medline, Embase, Cochrane Controlled Trials Register,
PubMed (National Library of Medicine), and the Cochrane
Library were searched to identify articles published and the
following keywords: HPV or Papillomavirus” OR “HPV
Vaccination” OR “HPV infection/epidemiology” OR “Papil-
lomavirus natural history” And (Italy and (prevalence or
incidence) OR (efficacy, burden, social equity, fertility, pre-
vention) And Male.
See flow diagram in Figure 1 that illustrates the results
of the entire process.
All the eligible papers were used by the four coordina-
tors to argue on their specific question and were included
in the references section. Among the eligible papers, those
supporting the question conclusions were reviewed by an
independent methodological expert and assessed with the
quality rating reports in Table 1.
During year 2010 the SP called 3 meetings with the SC
in order to examine the various revisions of the docu-
ment drawn together from scientific evidence for the
presentation of the results.
The final document with the results was presented on
22nd November 2010, by the SP and the SC to a Jury
called also a multidisciplinary Consensus panel of experts
composed of the following: 1 representative of the ethic
committee, 1 oncological gynecology, 1 pediatrician, 2 spe-
cialist of public health and epidemiology, 1 representative
of the Italian Medicines Agency (AIFA), 1 representative ofNational Institute of Health (ISS), 1 representative of the
Ministry of Equal Opportunities, 1 Member of “Cittadinan-
zattiva” (Active citizenship – an Italian non-profit orga-
nization of citizens).
Each question posed to the SC was discussed during
the day of the consensus.
On the basis of the document which was presented
and the lectures held by the SC during the consensus
meeting, the Jury reached a general agreement about the
information provided and how to answer to the key
questions, drawing from each questions recommenda-
tions based on their observations.
The document with the results of the work and there
commendations of the Jury was printed after the Consensus
Conference.Grading of scientific evidence
Various methods have been designed to assess the ro-
bustness of clinical recommendations. At present, an
international method is being developed, although it will
be difficult to reconcile different approaches and techni-
ques and include them all in a single assessment system
In the present case, the outline published in the British
Medical Journal in 2001 was followed (Table 1) [5].
Table 1 Grading of scientific evidence (5)
Grading Definitions
1++ High quality meta-analyses, systematic reviews of RCTs, or
RCTs with a very low risk of bias
1+ Well conducted meta-analyses, systematic reviews of RCTs, or
RCTs with a low risk of bias
1– Meta-analyses, systematic reviews or RCTs, or RCTs with a
high risk of bias
2++ High quality systematic reviews of case–control or cohort
studies or high quality case–control or cohort studies with a
very low risk of confounding, bias, or chance and a high
probability that the relationship is causal
2+ Well conducted case–control or cohort studies with a low risk
of confounding, bias, or chance and a moderate probability
that the relationship is causal
2– Case–control or cohort studies with a high risk of
confounding, bias, or chance and a significant risk that the
relationship is not causal
3 Nonanalytic studies, eg case reports, case series
4 Expert opinion
RCT Randomized and Controlled Trials.
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To carry out an in-depth review and reach an agreement
on the prevention of HPV-related diseases in males, which
is a complex healthcare issue that involves a number of
grey areas, the following list of questions was drawn up:
Question no. 1: What is the impact of HPV-related
diseases in males?
Question no. 2: What role does a positive test for HPV
infection in a partner play in the problems associated
with HPV-related diseases?
Question no. 3: What method of prevention of HPV-
related diseases could significantly reduce their impact
on the male population?
Question no. 4: Could primary prevention of HPV-
related diseases in men reduce HPV-related diseases in
their partners?Results
Question no. 1: What is the impact of HPV-related
diseases in males?
A) Prevalence of the infection [3] – Grading = 2++
In a systematic review by Dunne et al. on prevalence of
HPV in men [3] it was found to be as high as 72.9% and
the median probability of transmission per sex act was
around 40%. Table 2 reports the results of prevalence stud-
ies in which the polymerase chain reaction (PCR) was used
to detect the presence of the virus in multiple samples col-
lected from different anatomical sites that were deemed to
be most suitable for the purpose (e.g. the glans, sulcus andscrotum). The study populations varied, and included the
general population (workers, students), patients attending
STD clinics, healthy participants, and the partners of
women with HPV-related diseases (CIN1+). Studies that
didn’t took into consideration partners HPV positivity and
which included university students, military recruits, and
healthy, sexually active males, prevalence ranged between
6%–45%. The mean prevalence of positive tests in the
partners of women with cervical intraepithelial neoplasia
(CIN) lesions was higher (50–70%), whereas among males
recruited at clinics for sexually transmitted diseases
(STDs), the prevalence of positive tests was around 45%.
One of the most recent and significant studies, in terms of
population sampled, conducted by Giuliano et al. [6] in-
cluded 1.160 men in three countries, reporting a total
prevalence of 65.2% HPV positivity. Although not a review,
this study alone, adds more subjects than all previous stud-
ies placed together, making it one of the most statistical
significant studies on the subject.
B) The prevalence of infection by age [6] – Grading = 2+
In males, the prevalence of HPV does not differ signifi-
cantly among age group as it does in females [6]. Indeed,
prevalence in males remains high (50–70%) throughout
their lifetime, without any substantial decline with age. In
contrast, in women, the prevalence curve is consistently bi-
modal (with some geographical variability): there is a peak
after first sexual intercourse up to the age of 25–30 years,
followed by a decline up to the perimenopausal age, when
a second peak is often observed [24]. This pattern has been
observed in Italy too, according to an epidemiological
study conducted in Turin [25]. In the Turin study, the first
peak of HPV prevalence corresponded to 13–14% (with a
manifestation occurring up to the age of 39 years), after
which the prevalence decreased to 5% at the age of 45 years
and then increased to 8% during the perimenopausal
period. Another important difference between males and
females is the probability of acquiring an HPV genotype
that is associated with a high risk (HR) or a low risk (LR)
of oncogenicity (HR-HPV and LR-HPV, respectively).
Women seem to have a higher probability of acquiring an
HR-HPV [26], whereas the probability of acquiring the
two types of HPV appears to be similar in males (the
24-month cumulative incidence was 47.9% for HR vs
46.6% for LR) [27].
C) Incidence and clearance of the infection [27] –
Grading = 2+
The natural course of the disease has not been investi-
gated properly in males from an epidemiological point
of view, namely, by establishing rates of acquisition and
time to clearance of HPV infection. A few prospective
Table 2 Main prevalence studies conducted using the PCR method
Population type (n° males examined) Country Prevalence of positive
HPV DNA (PCR test)
Prevalence of positive HPV DNA
tests (high-risk genotypes)
Population (290) USA 30.0% 16.6%
Giuliano et al., 2007 [7]
Military recruits (285) Finland 16.5% - -
Hippelainen et al., 1993 [8]
University students (317) USA 32.8% 14.5%
Weaver et al., 2004 [9]
Students and industrial workers (114) Mexico 36.0% 16.7%
Lazcano-Ponce et al., 2001 [10]
Military recruits (337) Denmark 33.8% - -
Kjaier et al., 2005 [11]
Military men (1030) Mexico 44.6% 34.8
Lajous et al., 2005 [12]
University students (381) South Korea 8.7% 4.2%
Shin et al., 2004 [13]
Subjects attending STD clinics (235) Sweden 13.2% 8.1%
Wikstrom et al., 2000 [14]
Subjects attending STD clinics (198) Denmark 44.9% - -
Svare et al., 2002 [15]
Subjects attending STD clinics (393) US 28.2% 12.0%
Baldwin et al., 2003 [16]
Subjects attending STD clinics (85) Netherland 28.2% - -
Van Doornum et al., 1994 [17]
Subjects attending STD clinics (204) Japan 5.9% 5.9%
Takahashi et al., 2005 [18]
Males with female partner affected by CIN (119) Netherland 59.0% 55.4%
Bleeker et al., 2002 [19]
Husbands of women recruited in case–control studies on
carcinoma of the cervix (1143)
Thailand, Philippines, Brazil,
Columbia, Spain
16.0% - -
Franceschi et al., 2002 [20]
Males with female partner affected by CIN (181) Netherland 72.9% 58.6%
Bleeker et al., 2005 [21]
Males with female partner affected by CIN (77) Finland 9.1% - -
Hippelainen et al., 1994 [22]
Males with female partner affected by HPV (50) Brazil 70.0% - -
Nicolau et al., 2005 [23]
Males through 18–70 years from one of the three
sampling sites (1,160)
Brazil 65.2% 12.0% oncogenic types only
Giuliano et al., 2008 [6] Mexico
USA
PCR Polymerase Chain Reaction, CIN Cervical Intraepithelial Neoplasia.
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infection for heterosexual males. In a population of 290
male participants aged between 18 and 44 years (of whom
88% claimed to be heterosexual), who were followed up for
a mean period of 15.5 months [27], the overall prevalenceof HPV infection (any genotype) was 30%, the period pre-
valence (positive test at any time in the study) was 52.8%,
and the incidence of infection amounted to 29.4 per 1,000
person–months. The incidence of new infections, as mea-
sured in males with a negative HPV test at recruitment,
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survival curves, it was estimated that the rate of acquisition
of new infections was 29.2% over 12 months (19% for
HR-HPV vs 16% for LR-HPV), and the rate of acquisition
of the HR genotypes 16 and 18 (5.1% of new infections)
was higher than that of LR genotypes 6 and 11 (3.4% of
new infections). The mean clearance time (defined as the
time to elimination of 50% of all infections) was estimated
to be 5.9 months (95% CI: 5.7–6.1). HPV DNA was no
longer detectable in 75% of infected subjects 12 months
from onset of the infection, without any differences bet-
ween HR-HPV and LR-HPV, after 5.9 months [27].
The study by Partridge [27], which was conducted
in a population of 240 male university students aged
18–23 years, yielded a prevalence of 25.8% and estimated
a cumulative incidence at 24 months of 62.4% (95% CI:
52.6–72.2) for all HPV genotypes. The incidence of HR-
HPV and LR-HPV genotypes was similar (approximately
48%). The glans, the shaft of the penis, and the scrotum
had the same probability of being infected (44%); whereas
the positive test rate of urinary samples was much lower
(7–8%) [27].
D) HPV-related diseases in males
The HPV-related diseases that occur in males are geni-
tal warts and cancers of the penis, anus, oral cavity, and
oropharynx (carcinomas of the head and neck).
➣ Anogenital warts [7,28,29] (grading = 2–, 3, 2+,
respectively)
In most cases (90%), anogenital warts are caused by
HPV genotypes 6 and 11 [7]. In Italy, the HPV
infection and genital warts is not subject to mandatory
reporting, according to an investigation at 12 STD
centres attended by a high-risk population, genital
warts were diagnosed in 33% of subjects, 73% of whom
were male. The mean age and standard deviation (SD)
of the male population was 33.6 (±11.0) years, whereas
the mean age (SD) of the female population was 30.9
(±10.9). The distribution by age bracket showed that
the proportion of anogenital warts was higher in the
14–25-year age group than in the older age brackets, in
both males and females. In Italy, genital warts in STD
clinics showed that in males, 89.9% of anogenital warts
were diagnosed in self declared heterosexual men and
10.1% in self declared bisexuals or homosexuals [28].
Data showed that in Italy through STD clinics, genital
HPV infections is the most diagnosed STI in Italy, this
study is important as it is the only study on genital
warts incidence as it is not a reportable disease. Genital
warts show a high spread among young people both in
males and females.Having ≥ 2 sexual partners in the last 6 months
(reported by 50.3% of males) and the presence of other
concomitant STDs (recorded in 17.1% of males) were
risk factors [28]. In a study conducted in Italy in 2008,
it was estimated that the number of cases of anogenital
warts per year in women aged between 14 and 64 years
was approximately 120,000 (with a prevalence that
corresponded to 0.6%) [28,29].
➣ Cancer of the penis [30-32] (grading = 2–, 2–, 2–,
respectively)
Cancer of the penis is a rare tumor in Western
countries. It has been estimated that around 1,000
cases of HPV-related cancer of the penis occur in
Europe every year. HPV DNA is detected in
approximately 40–50% of all cases of cancer of the
penis, and seroepidemiological studies have shown that
the main genotypes involved are HPV 16 and 18
[30-32]. No studies are available in Italy.
➣ Cancer of the anus [33,34] (grading = 2–, 2–,
respectively)
The HPV virus is detected in 80% of cancerous lesions
of the anus, and genotype 16 is the subtype that is
involved most commonly (87%). In the USA, the
incidence of cancer of the anus increased considerably
between 1970 and 2000. Its incidence is particularly
high in homosexual males and the risk is increased
even further in the presence of human
immunodeficiency virus (HIV) infection. It has been
estimated that, in Europe, something like 2,000 cases of
cancer of the anus occur in males every year [33,34].
➣ Carcinomas of the head and neck [16] (grading = 2–)
The overall prevalence of HPV DNA in carcinomas of
the head and neck is approximately 26% and it reaches
a peak of 36% in cancer of the oropharynx. HPV-16 is
the genotype involved most commonly (60–80%).
Furthermore, a significant association has been found
between HPV in the oral cavity and sexual habits [16].
E) HPV and fertility [35-38] – Grading = 3, 3, 2–, and 3,
respectively
Preliminary studies show not only that HPV is present
in semen, but that it might reduce sperm motility prob-
ably causing reduced fertility in males. Moreover, the
virus might interfere with the development of the
embryo in animal models according to some studies
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ther studies are needed in order to clarify its relationship
with fertility.
F) Diagnosis of HPV in males [39-41] – Grading = 2+,
2++, 2–, respectively
At the moment, there is no generally accepted and
validated test for screening HPV in males in the clinical
practice. However, there is a general consensus on when
diagnostic testing should be performed, which may be
summarized as follows [39-41]:
1. When the patient has a partner who is HPV positive
or has an HPV-related disease;
2. When HPV-related clinical manifestations are
present;
3. When the patient has sex with men.
At present, molecular methods are used most com-
monly, both to detect infection and to identify the virus
genotype. The tests are based on amplification methods
(PCR) with hybridization [42]. Cell samples for the HPV
test may be collected from multiple sites (penis shaft;
balano-preputial sulcus; glans; navicular fossa of the ur-
ethra; scrotum; the pubic, perianal, and anal areas; the
oral cavity; the oropharynx; and the larynx), possibly
from suspicious lesions [31,43].
For males, a test that identifies not only HR-HPV but
also LR-HPV and genotypes associated with intermediate
risk or that have not been classified yet would be useful,
because it may enable differential diagnoses to be made be-
tween benign and malignant lesions and those related or
not related to HPV (e.g. molluscum contagiosum) [44-46].
G) Follow-up of male patients with HPV-related
diseases [47,48] – Grading = 4, and 1 (according to
the Guidelines of the Italian Society of Virology)
The following investigations are suggested for the
follow-up of HPV-related diseases:
➣ According to the site involved, benign lesions
should be checked clinically with genitoscopy and/or
anoscopy every 4 months for the first year, as
appropriate. Molecular analysis to screen for HPV
should be carried out with the same frequency;
➣ In subjects at risk (those with neoplastic lesions or
with a history of HPV-related neoplasias), testing for
HPV DNA should be carried out every 4 to 6 months;
➣ In subjects with a greater risk of infection and
disease development (immunodepressed, HIV-positiveand/or homosexual subjects), testing for HPV should
be carried out every 8 to 12 months;
➣ In asymptomatic HPV-positive subjects, laboratory
follow-up is recommended after 8 to 12 months to
assess the persistence or clearance of the infection and
to check whether any lesions have developed.
Question conclusions
According to the answers given by the SC, Impact of
HPV-related diseases seem to be high in males. Not the
same burden as in women for high risk HPV types related
lesions but more when taking into account only low grade
HPV related lesions such as genital warts. Prevalence
seems to be higher than in women irrespective of age and
no standardized HPV test guidelines are recommended as
in women. Preliminary fertility studies in men seem to
show that HPV might have an important role, more stud-
ies and data need to be done in order to prove HPV rela-
tion with fertility.
Conclusive considerations of the consensus panel
➣ More prevalence studies in males should be
conducted. In Italy, notification of HPV related diseases
such as genital warts are not mandatory, more
epidemiological data is needed in order to evaluate
disease impact.
➣ More scientific studies should be made about data
on the standardized collection of biological samples
and method of testing used for HPV detection in males
in order to implement in the future standard
recognized sampling and diagnostic tests in eventual
prevention and screening programs.
➣ Further research on the issue of HPV and fertility
worldwide is required in order to fully understand if it
is related and affected by HPV and in what measures
HPV vaccination might reduce this.
Question no. 2: What role does a positive test for HPV
infection in a partner play in the problems associated
with HPV-related diseases?
A) Transmission potential of the virus [1,2,27,49] –
Grading = 2++, 2++, 2++, and 2+, respectively
HPV is a highly contagious virus that is widespread in the
environment. It is transmitted mainly through sexual con-
tact. However, indirect secondary modes of transmission
also exist (contact of skin with skin, hetero-inoculation
mediated by the hands, contact with underwear or inani-
mate objects) [1,2,27,49]. To assess the role that males
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studies on couples appear to be more relevant than popula-
tion studies. Interestingly enough, most studies are focused
on long term relationship, or relationships on which the fe-
male partner is affected of an HPV lesion such as CIN, little
is known about recently established relations at an early
age, that can help understand HPV dynamics, natural his-
tory and transmission models in young couples. HPV con-
cordance data is variable throughout different studies. In
Studies conducted in couples that had a mean duration
time of 10 years of relationship, concordance of at least one
HPV type in couples that were both positive for HPV was
of 57.8% [21] which is more prevalent than expected by
chance, other studies conducted in Italian couples, demon-
strate also high HPV concordance in infected couples of
around 45% [50]. Both studies show high HPV infection
rates irrespective of HPV type, especially when the fe-
male partner is already infected, concordance rates might
be important to understand transmission dynamics that
are important for persistent infections and development
of lesions. In recently established couples, according to
Burchell et al., the rate of HPV infections was around
64%, of which concordance was found in 41% of the het-
erosexual couples [51], even in a young recently made
couple (aged 18–24) HPV infection and concordance was
higher than expected by chance. In time new most newly
made couples will probably clear infection, even so high
prevalence and concordance with time, like in long term
relationships, might explain persistent infection dyna-
mics and explain in part increased lesion development
risks. Genotype concordance in couples could depend on
several variables: behavioural variables (frequency, type,
duration of sexual contact and protection measures), bio-
logical variables (different susceptibilities and clearance
abilities of tissues in the two genders), and probably others
that have not yet been identified.
B) Transmission dynamics [50,52-54] – Grading = 2–,
2++, 2++, and 2+, respectively
Transmission of the virus from one partner to another
varies also according to sexual practices. Many male
partners may be classified as «healthy carriers» who un-
knowingly serve as an asymptomatic reservoir and could
contribute to the development of HPV-related diseases
in women [52-54].
C) Risk factors and monitoring [27,55-58] – Grading =
2++, 2–, 2–, 2+, and 4, respectively
In males, age does not appear to be related clearly to
the acquisition of the infection. In general, sexual habits
(duration of sexual activity and number of recent part-
ners) correlate with the presence of infection, in bothmales and females. Individual factors (age at first sexual
intercourse, number of partners while sexually active,
smoking habits, and alcohol consumption) or factors
related to the female partner (anal sex, partner with a
history of STD) are not related consistently and signifi-
cantly to the acquisition of infection and its presence in
males [3,4,27]. In addition, a state of immunodeficiency
(due to HIV infection) is a risk factor for infection of
HPV [55-57]. Every male sexual partner of a woman af-
fected by anogenital warts should be examined to detect
and, if necessary, treat any esophytic HPV-related le-
sions. It is important to extend monitoring beyond the
mean incubation period (3 months) [58]. At present,
testing for HPV (through PCR) in asymptomatic males
with a negative examination of the penis (penoscopy) is
not recommended, even when the female partner has
had a positive cytological examination [58].
Question conclusions
Based on the previous statements and data, HPV DNA
sero status seem to play a fundamental role in HPV trans-
mission and diseases development between partners. In
males, there are several risk factors that play a fundamen-
tal role in HPV infection and development of the disease
such as immunodeficiency disease.
Conclusive considerations of the consensus panel
➣ Awareness campaigns should be implemented not
only for anogenital warts but for HPV-related diseases
in general, through all institutional channels, in order
to increase HPV knowledge and reduce, when possible,
HPV transmissibility at a population level.
➣ Subjects with an immunodeficiency status, such as
HIV, have a greater risk of HPV infection; prevention
strategies should also target high risk populations.
Question no. 3: What method of prevention of HPV-
related diseases could significantly reduce their impact
on the male population?
A) Primary Prevention [59-68] – Grading = 1++, 1++,
1++, 1++, 1++, 1++, 1++, 1+, 1++, and 2+,
respectively.
Primary prevention through vaccination has proved to
be very effective in preventing precancerous lesions and
cancers of the cervix, vulva, and vagina, as well as ano-
genital warts, in women up to the age of 45 years [59-66].
The quadrivalent vaccine is effective against HPV geno-
types 6, 11, 16, and 18. In Europe, the vaccine is indicated
for the prevention of cervical cancer, precancerous lesions
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in women aged between 9 and 45 years [69].
Clinical trials have shown that the quadrivalent vaccine
is effective in preventing external genital lesions (anogeni-
tal warts, as well as penile and perineal lesions) in males
aged between 16 and 26 years in 90.4% (95% CI: 69.2–98.1)
of cases [67]. On the basis of these results, in October
2009, the US Food and Drug Administration (FDA) ap-
proved the extension of the indications for the quadrivalent
vaccine to males up to the age of 26 years, for the preven-
tion of anogenital warts. In addition to the USA, another
seven countries have approved the extension of the indica-
tions for the quadrivalent vaccine to males up to the age of
26 years for the prevention of anogenital warts [70].
At present, efficacy data on the quadrivalent vaccine
with respect to the prevention of external genital and anal
precancerous lesions are available (Table 3). In a subpopu-
lation of homosexual males aged between 16 and 26 years,
population at a higher risk of anal precancerous lesions,
the quadrivalent vaccine was effective in 77.5% (95% CI:
39.6–93.3) of cases in preventing precancerous anal le-
sions (per-protocol analysis); furthermore, in a post-hoc
analysis, the efficacy rate was 91.7% (95% CI: 44.6–99.8)
[71,72] specifically from HPV types 16 and 18.
Notes of importance after the consensus:
In accordance to the importance and recommenda-
tions already stated by the CC document about HPV in
males, in late 2010 and 2011, on the basis of vaccine effi-
cacy data against HPV-related anal precancerous lesions,
in December 2010, the FDA approved the extension of
the indications for the quadrivalent vaccine to the pre-
vention of anal cancer and anal intraepithelial lesions in
males and females aged between 9 and 26 years [73]. In
addition, the results for efficacy related to the prevention
of anal cancer and anogenital warts in males aged 16–26
were taken into consideration by the European Medi-
cines Agency and resulted in the extension of indication
of the quadrivalent vaccine in males 9–26 years of age
for the prevention of genital warts.Table 3 Efficacy of the quadrivalent vaccine in preventing ex
Giuliano [67]
Population Per-protocol
(16–26 years)
External genital lesions 90.4%
(95% CI: 69.2–98.1)
AIN
Anogenital warts 89.4%
(95% CI: 65.5–97.9)
* Post-hoc analysis. AIN Anal intraepithelial neoplasia.B) Condoms [74,75] – Grading = 1+, and 2+,
respectively
The use of a condom reduces, albeit not completely,
the risk of transmission of HPV infection between het-
erosexual partners. Moreover, correct and consistent use
of a condom reduces the risk of transmission by ap-
proximately 50% and appears to promote clearance of
the infection as seen on a randomized trial conducted in
women diagnosed with CIN lesions and their partners,
in the group that used condom, correct usage seemed to
promote regression of CIN lesions and clearance of
HPV infection on both [74]. Condom usage also reduces
the risk of HPV infection in males from female infected
partners [75].
Question conclusion
Vaccination on males, according to recent data, seems to
be effective with the quadrivalent vaccine as it is in women.
Vaccination is the most effective measure to reduce HPV
related diseases impact in males with efficacy rates around
90%. Condom usage seems to be also effective in redu-
cing at least in 50% the risk of transmission when used
correctly.
Conclusive considerations of the consensus panel
➣ An awareness campaign should be implemented
about available vaccines, the importance of vaccination
and its high efficacy in males. Also about other
prevention measures such as condom usage, through
all institutional channels.
➣ The quadrivalent HPV vaccine has proven to be
effective in protecting males against genital warts and
HPV related precancerous anal lesions. Based on
vaccine efficacy results, male vaccination should be
recommended as in females as they can benefit too
from vaccination.ternal genital lesions and AIN (per-protocol population)
Palefsky [71] Goldstone [72]
Per-protocol Per-protocol*
(16–26 years) (16–26 years)
77.5% 91.7%
(95% CI: 39.6–93.3) (95% CI: 44.6–99.8)
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diseases in men reduce HPV-related diseases in their
partners?
A) Vaccination [76] – Grading = 2–
Little data is still available about vaccination effect on
a population level. Only on the years to come data will
become more available and valid. Only one ecological
study, obtained from vaccination programs carried out
in women in Australia, were vaccination coverage is high
on women, although still early have shown that vaccin-
ation induces also some herd immunity in men i.e. there
is a partial reduction in the occurrence of anogenital
warts in heterosexual males compared to vaccinated
women. In Australia, the quadrivalent vaccine has been
administered to schoolgirls aged between 12 and 18 years
and to women younger than 26 years since 2007. The
coverage rate in the area where the study was conducted
ranged from 65% to 75%. One year after the implemen-
tation of the mass vaccination program, comparison of
the rates of diagnosis of anogenital warts before and
after the introduction of vaccination showed a 48% re-
duction in the diagnosis of anogenital warts in women
younger than 28 years, but no corresponding reduction
was obtained in women older than 28 years and in the
males who have sex with males population [76].
Over the same period, a 17% reduction in the diagnosis
of genital warts among heterosexual males was recorded.
This reduction was not observed in homosexual males, a
finding that suggests some herd immunity effect. In other
words, use of the vaccine confers indirect protection on
the unvaccinated population as a result of the reduction in
the total number of infected subjects, which in turn
decreases the number of potentially infectious contacts.
B) Reduction in HPV-related events [77,78] – Grading =
Publications could not be assessed, because they are
abstracts or other types of communication
In view that natural history in males, although explained,
still lacks further research as today we know that although
similar, it does not behave as in females and because of the
paucity of established epidemiological data, it is impossible
(at the moment) to provide details on the impact of a pri-
mary prevention strategy on the reduction of HPV-related
disease in partners
The complexity of the scenario produced by the imple-
mentation of primary prevention in males is due to a
number of general considerations: 1) there is limited in-
formation on the natural history of HPV infection in
males, that behaves differently than females (incidence,
prevalence, seroprevalence and burden of disease is dif-
ferent), information is still scarce and more studies arestill needed; 2) the inconsistencies of epidemiological
data and rates of concordance of genotypes among cou-
ples (which are in turn modulated by differences in sex-
ual behavior, age, relationship time and by the diagnostic
method adopted among other factors); 3) The lack of a
reliable and validated monitoring and diagnosis system
(in the long and short term) for males.
Given that HPV infection is a sexually transmitted dis-
ease, interventions for primary prevention in one partner
will evidently have a positive effect in terms of reducing
HPV-related disease in the other partner. Mathematical
models indicate that the cost–effectiveness ratio for the
vaccination of males becomes favorable in the presence
of a low coverage rate for females, because it can con-
tribute towards the containment of infection in the com-
munity [77,78], some even state that it becomes more
cost effective to vaccinate males rather than hard to
reach women [79]. As a result, herd immunity from vac-
cinating only women is likely to be insufficient to eradi-
cate HPV infection, in fact, on the other hand, a single
sex HPV vaccination campaign may also increase the
psychological burden on women [80], and this sex in-
equality could amount to an additional healthcare bur-
den. As a disease that affects both men and women,
social fairness needs to be taken into consideration as
both individually can benefit from the vaccine. There’s
also the matter of males who have sex with males, to
whom no benefit is gained from female vaccination
only as shown in early ecological studies [76]. In ad-
dition, lessons learned from history, seem to show
that single gender vaccination campaigns, such as the
one against rubella in 1996, that although both diseases
differ significantly, there are several potential pitfalls in
single sex vaccine programs [81]. From this perspective, it
remains to be seen whether the current objective of the
vaccination program in Italy will be achieved, namely
95% coverage with three doses of vaccine within 5 years
from the start of the program. The available data for the
1997 born cohort (updated to 31 December 2009) indi-
cate that the coverage rate at 3 vaccine doses is only
53.1% [82].Question conclusions
Although herd immunity exist, primary vaccination
exclusively of males or females doesn’t seem to be ef-
fective when coverage rates are less than high in reducing
HPV related disease on partners in a significant way. In
Italy coverage rates are not high, only 53% of 12 years
old females have been vaccinated with 3 doses. Social
equity right to get the vaccine in males and higher
risk groups, as well as social burden (including psycho-
logical burden) should be taken into consideration as they
seem relevant.
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➣ When vaccination campaigns targets only one
gender, vaccine coverage should be very high in order
to expect significant effects in the other gender
morbidity.
➣Were possible, vaccine programs to both genders
should be implemented as they seem to be more
effective.
➣ More initiatives should be directed towards the
population raising awareness of primary prevention, in
order to achieve high vaccination coverage in the
already implemented vaccination campaign in females
to guaranty at least some herd immunity in males.
➣ Specific efforts should be made to vaccinate higher
risk groups such as immunosuppressed subjects.
Conclusions
Consensus conference statements and final remarks
On the evidence presented by the 4 main questions made
to the SC by the SP, the Jury composed by the multidiscip-
linary consensus panel agrees that HPV (human papillo-
mavirus) impact is important in males. Based on the
specific scientific data analyzed and the conclusive consid-
erations the multidisciplinary consensus panel made, they
conclude the following recommendations:
Recommendations made by a majority
➣ For prevention purposes and social fairness, 12-year-
old males should be vaccinated. The jury did not deal
with aspects related to healthcare policy and economic
sustainability, which are to be discussed elsewhere by
others.
Unanimous recommendations
➣ The Regions of Italy should introduce an HPV
vaccination program with facilitated access (reduced
price) for males, as they have done already for females.
➣ More initiatives should be directed towards the
population raising awareness of primary prevention and
disease. As a result, vaccination coverage rates may
improve in the ongoing vaccination campaign in
females to indirectly reduce some of male’s morbidity.
➣ Specific efforts should be made to vaccinate groups
at higher risk of infection and HPV disease
development such as immunosuppressed subjects,
especially HIV + .➣ Awareness campaigns of new scientific evidence
should be implemented not only for anogenital warts
but for HPV-related diseases in general, through all
institutional channels.
➣ Further research on the issue of HPV and fertility
worldwide is required in order to fully understand if it
is really caused by HPV and in what measures infertility
rates can be reduced by HPV prevention measures
such as vaccination.
➣ Prevalence and incidence studies in males should be
further conducted. In Italy, notification of HPV related
diseases such as genital warts are not mandatory, more
epidemiological data is needed in order to evaluate
disease burden.
➣ Scientific studies should be conducted about the
standardized collection of biological samples and
testing methods used for HPV detection in males in
order to implement in the future standardized
guidelines on sampling and diagnostic tests in males.
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